At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
Halobetasol Proprionate Lotion 0.05% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating Halobetasol Proprionate Lotion 0.05% and Halobetasol Proprionate Cream 0.05% for Plaque Psoriasis. Completed, enrolled 43 participants across 5 sites.
Detailed Summary
The purpose of this study is to determine whether the investigational lotion is an effective treatment of moderate to severe plaque psoriasis in comparison to an approved cream.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedJul 2010
Primary CompletionJul 2011
TodayJul 2026
First PostedJul 21, 2010
Enrollment StartJul 1, 2010
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.9 years ago
Interventions
Halobetasol Proprionate Lotion 0.05%drug
Apply 3.5 grams twice daily for 1-2 weeks
Halobetasol Proprionate Cream 0.05%drug
Apply 3.5 grams twice daily for 1-2 weeks